Atypical Targetoid Lesions as the Presenting Sign of Myeloid Sarcoma

Main Article Content

Eduardo Adrian Rodriguez
Edward Visnaw
Frank Petr
Huma Siddiqui


Myeloid sarcoma, Targetoid


Myeloid sarcoma (MS), also known as chloroma or granulocytic sarcoma, is a rare extramedullary tumor mass that commonly occurs in acute myeloid leukemia (AML). MS may occur before other clinical signs of AML, or alongside other known AML symptoms. MS can also appear in isolation, which makes diagnosis challenging. Clinical knowledge about a typical presentation of myeloid sarcoma is limited, given the heterogeneity in the location and size of MS lesions. We describe a patient with a history of AML who developed an eruption of atypical targetoid purpuric lesions. Diagnostic workup, including laboratory and histologic specimen from the skin were consistent with MS. MS should be suspected in a patient with a history of myeloproliferative disorder who develops atypical targetoid purpuric papules.


1. Meyer H, Beimler M, Borte G, Pönisch W, Surov A. Radiological and Clinical Patterns of Myeloid Sarcoma. Radiology and Oncology. 2019;53(2):213-218. doi: 10.2478/raon-2019-0014.

2. Campidelli C, Agostinelli C, Stitson R, Pileri SA. Myeloid sarcoma: extramedullary manifestation of myeloid disorders. American journal of clinical pathology. 2009;132(3):426-

3. Kaur V, Swami A, Alapat D, et al. Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. Hematology. 2018;23(1):17-24. doi:10.1080/10245332.2017.1333275

4. Neiman RS, Barcos M, Berard C, et al. Granulocytic sarcoma: A clinicopathologic study of 61 biopsied cases. Cancer. 48(6):1426-1437. doi:10.1002/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-G

5. Kawamoto K, Takizawa J, Sone H, Miyoshi H, Yoshida N, Ohshima K. Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients. American Journal of Surgical Pathology. 40(11):1473-1483. doi:10.1097/PAS.0000000000000727

6. Almond LM, Charalampakis M, Ford SJ, Gourevitch D, Desai A. Myeloid Sarcoma: Presentation, Diagnosis, and Treatment. Clinical Lymphoma, Myeloma & Leukemia. 2017;17(5):263-267. doi: 10.1016/j.clml.2017.02.027.

7. Klco JM, Welch JS, Nguyen TT, et al. State of the art in myeloid sarcoma. International Journal of Laboratory Hematology. 2011;33(6):555-565. doi: 10.1111/j.1751-553X.2011.01361.x

8. Katagiri T, Ushiki T, Masuko M, et al. Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: A case report and literature review. Medicine. 2017;96(36):e7975. doi:10.1097/MD.0000000000007975

9. Antic D, Elezovic I, Milic N, et al. Is there a “gold” standard treatment for patients with isolated myeloid sarcoma? Biomedicine & Pharmacotherapy. 2013;67(1):72-77. doi:10.1016/j.biopha.2012.10.014

10. Kawamoto K, Miyoshi H, Yoshida N, Takizawa J, Sone H, Ohshima K. Clinicopathological, Cytogenetic, and Prognostic Analysis of 131 Myeloid Sarcoma Patients. The American journal of surgical pathology. 2016;40(11):1473-1483. Accessed August 19, 2020.

11. Niiyama S, Amoh Y, Watarai A, Katsuoka K, Mukai H. Cutaneous myeloid sarcoma presenting as grey pigmented macules. Acta dermato-venereologica. 2012;92(6):629-630. doi:10.2340/00015555-1312

12. Hurley MY, Ghahramani GK, Frisch S, et al. Cutaneous Myeloid Sarcoma: Natural History and Biology of an Uncommon Manifestation of Acute Myeloid Leukemia. Acta Dermato-Venereologica. 2013;93(3):319-324. doi:10.2340/00015555-1458

Most read articles by the same author(s)